Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
- BTIG cut the price target for Abbott Laboratories (NYSE:ABT) from $140 to $131. BTIG analyst Marie Thibault maintained a Buy rating. Abbott shares closed at $101.88 on Monday. See how other analysts view this stock.
- HC Wainwright & Co. cut BTCS Inc. (NASDAQ:BTCS) price target from $7 to $5. HC Wainwright & Co. analyst Kevin Dede maintained a Buy rating. BTCS shares closed at $1.29 on Monday. See how other analysts view this stock.
- Needham slashed price target for Phreesia, Inc. (NYSE:PHR) from $35 to $14. Needham analyst Ryan MacDonald maintained a Buy rating. Phreesia shares closed at $11.41 on Monday. See how other analysts view this stock.
- HC Wainwright & Co. raised the price target for Bicara Therapeutics Inc. (NASDAQ:BCAX) from $40 to $42. HC Wainwright & Co. analyst Robert Burns maintained a Buy rating. Bicara Therapeutics shares closed at $19.04 on Monday. See how other analysts view this stock.
- Baird cut nCino, Inc. (NASDAQ:NCNO) price target from $34 to $24. Baird analyst Joe Vruwink maintained an Outperform rating. nCino shares closed at $14.42 on Monday. See how other analysts view this stock.
- B of A Securities raised Shake Shack Inc. (NASDAQ:SHAK) price target from $88 to $101. B of A Securities analyst Sara Senatore upgraded the stock from Underperform to Neutral. Shake Shack shares closed at $83.53 on Monday. See how other analysts view this stock.
- Baird cut Corpay, Inc. (NYSE:CPAY) price target from $440 to $380. Baird analyst David Koning maintained an Outperform rating. Corpay shares closed at $290.36 on Monday. See how other analysts view this stock.
- BMO Capital cut the price target for Phreesia, Inc. (NYSE:PHR) from $32 to $14. BMO Capital analyst Sean Dodge maintained an Outperform rating. Phreesia shares closed at $11.41 on Monday. See how other analysts view this stock.
- HC Wainwright & Co. cut Viridian Therapeutics, Inc. (NASDAQ:VRDN) price target from $34 to $22. HC Wainwright & Co. analyst Douglas Tsao maintained a Buy rating. Viridian Therapeutics shares closed at $18.53 on Monday. See how other analysts view this stock.
- Canaccord Genuity cut USA Rare Earth, Inc. (NASDAQ:USAR) price target from $33 to $29. Canaccord Genuity analyst George Gianarikas maintained a Buy rating. USA Rare Earth shares closed at $14.23 on Monday. See how other analysts view this stock.
Considering buying BCAX stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments